Mind Medicine (NEO: MMED) this morning announced that it has submitted an application to uplist its stateside cross-listing to that of the Nasdaq Capital Market from the OTCQB. The submittal of an application is part of the firms goal of “evaluating an expanded United States investor base.”
Canaccord Genuity has been appointed as financial advisor in connection with the application, whom is said to be assessing the viability of such a move by the company. Canaccord is also said to be evaluating potential M&A opportunities for the firm.
No further information on the Nasdaq application was provided by the company, aside from the statement that no assurances can provided that the Nasdaq will approve of the application.
The appointment of Canaccord as financial advisory notably follows the news last week that Canaccord initiated coverage on the firm with a $1.75 price target.
Mind Medicine last traded at $0.53 on the Neo.
Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
The Grocery Grift: Why Toronto and New York Are About to Light Taxpayer Money on Fire